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Graphical abstract. 
The regulation of cardiac development by miRs and lncRNAs, and their interaction in 
pathological setting. 
 
Abstract  
 Non-coding RNAs (ncRNAs) are emerging players in muscle regulation. Based on 
their length and differences in molecular structure, ncRNAs are subdivided into several 
categories including small interfering RNAs, stable non-coding RNAs, microRNAs (miRs), 
long non-coding RNAs (lncRNAs), and circular RNAs. miRs and lncRNAs are able to 
post-transcriptionally regulate many genes and bring into play several traits 
simultaneously due to a myriad of different targets. Recent studies have emphasized 
their importance in cardiac regeneration and repair. As their altered expression affects 
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cardiac function, miRs and lncRNAs could be potential targets for therapeutic 
intervention. In this context, miR- and lncRNA-based gene therapies are an interesting 
field for harnessing the complexity of ncRNA-based therapeutic approaches in cardiac 
diseases. In this review we will focus on lncRNA- and miR-driven regulations of cardiac 
development and repair. Finally, we will summarize miRs and lncRNAs as promising 
candidates for the treatment of heart diseases. 
 
 
Key words: miRs and lncRNAs, cardiac development and repair, ncRNA-based 
therapies, exosomes  
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AAV: adeno-associated virus 
AMI: acute myocardial infarction 
APF: autophagy promoting factor 
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CARMEN / Carmen: cardiac mesoderm enhancer-associated non-coding RNA 
CHAER / Chaer: cardiac-hypertrophy-associated epigenetic regulator 
CHAST / Chast: cardiac hypertrophy associated transcript 
CHRF: cardiac hypertrophy related factor  
circRNA: circular RNA 
elncRNA: enhancer-associated long non-coding RNA 
ESC: embryonic stem cells 
EZH2: enhancer of zeste homolog 2 
FENDRR / Fendrr: Fetal-lethal or Foxf1 adjacent non-coding developmental regulatory 
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HF: heart failure 
KO: knockout 
LNA: locked nucleic acid 
lincRNA: long intergenic non-coding RNA 
lncRNA: long non-coding RNA 
Mesp1: mesoderm posterior basic helix-loop-helix transcription factor 1 
MHRT / Myheart: myosin heavy chain associated RNA transcripts 
MIAT: myocardial infarction-associated transcript 
miR: microRNA 
mRNA: messenger RNA 
MyHC: myosin heavy chain 
ncRNA: non-coding RNA 
PRC2: Polycomb Repressive Complex 2 
RISC: RNA-induced silencing complex 
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ROR: regulator of reprogramming 
snoRNA: stable non-coding RNA 
SUZ12/Suz12: suppressor of zeste 12 protein homolog 
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1.  Introduction: miR and lncRNA biogenesis and delivery  
Non-coding RNAs (ncRNAs) represent a class of transcripts with high density of 
stop codons and lacking extensive ‘Open Reading Frame’ (ORF) [1]. However, several 
studies using genome-wide techniques (mass spectrometry proteomics, deep RNA 
sequencing, ribosome profiling) are shedding light on possible cryptic ORFs inside 
ncRNAs that sparked controversy in the real nature of ncRNAs [2]. ncRNAs are 
commonly considered as RNA transcripts that, although not having a direct protein-
coding potential, are biologically functional RNAs with fine-tuned mechanism of protein-
coding gene regulation. 
Early studies carried out in 1991 by Bartolomei et al. in mice discovered the first 
ncRNA (H19) spanning 2.5-kilobase. The authors demonstrated the crucial role of H19 
not only in mouse development but also in imprinting, as only the maternally-inherited 
allele was shown to be active [3]. After this finding, several ncRNAs have emerged for 
their role in imprinting, such as Xist [4]. The discovery of ncRNAs changed the central 
dogma of molecular biology ‘DNA makes RNA makes proteins’ stated by Francis Crick 
[5]. Indeed, in the early 1960s it was believed that only a small fraction of genome 
(around 2%) was covered by protein-coding genes, while the remainder (up to 97% of the 
entire genome) was made of non-transcribed ‘junk DNA’ regions [6,7]. However, with the 
birth of the ENCODE Project in 2000 (see https://www.encodeproject.org/) that aimed to 
characterize all the functional elements in the human genome, huge steps forward were 
made in order to understand the eukaryotic genome complexity [7]. In fact, the ENCODE 
project helped researchers in reshaping the concept of ‘junk DNA’ by implementing new 
genome-wide techniques (tiling microarrays, RNA-seq, ChIP-seq, FAIRE-seq) with 
computational tools, such as protein-coding gene prediction software, to uncover the role 
of non-transcribed DNA regions. By means of whole transcriptome analyses, it was 
uncovered that up to 90% of the eukaryotic genomic DNA is transcriptionally active, 
including RNAs lacking their coding function, i.e. ncRNAs. A study from 2007 
strengthened the idea that ncRNAs are crucial in the evolutionary scale [8], since it was 
demonstrated that the evolution of biological complexity in any given organism relies on 
the number of non-protein-coding genes rather than the number of protein-coding genes 
[9].  
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 Researchers have classified ncRNAs into three different subgroups based on their 
length [10]: 
1) Short-sized ncRNAs, including microRNAs (miRs) [18-24 nucleotides], short 
interfering RNAs [~ 21 nucleotides] and piwi-interacting RNAs [26-31 nucleotides];  
2) Medium-sized ncRNAs including stable non-coding RNAs [60-300 nucleotides]; 
3) Long-sized ncRNAs, including long intergenic ncRNAs (lincRNAs), transcribed 
ultraconserved ncRNAs and other long ncRNAs (lncRNAs) [>200 nucleotides]. 
In this review we will focus on miRs and lncRNAs due to their main relevance for 
potential therapeutic strategies in cardiovascular diseases. 
 MiRs are conserved non-protein-coding RNA molecules with a typical length of 
~22 nucleotides. Currently 2,588 sequences of mature miRs are reported in humans, 
while 1,915 mature miRs are described in mice (see mirbase.org). MiRs regulate gene 
expression by the unique mechanism of directly targeting protein-coding and non-coding 
genes, leading to post-translational gene silencing. Moreover, miRs have a pleiotropic 
effect as they can target hundreds of mRNAs [11].  
The genes encoding for miRs are represented in the genome as intergenic 
clusters or independent transcriptional units. MiRs derive from either introns or exons of 
both protein-coding and non-coding genes [12,13]. During their biogenesis, miRs are 
synthesized by RNA polymerase II and, to a lesser extent, by RNA polymerase III [14]. 
RNA polymerase II transcribes miR genes into pri-miRs, accounting for long primary 
transcripts. pri-miRs have secondary stem-loop structure and incorporate a 5′ cap and 3′ 
polyadenylation tail. Subsequently, the microprocessor complex, made up by RNase-III 
Drosha and its co-factor Dgcr-8, cleaves the pri-miRs into pre-miRs, which are ~70 nt-
long precursor molecules [15]. Pre-miRs are then shuttled into the cytosol by a nuclear 
export protein called exportin-5. Once inside the cytosol, the RNase-III Dicer and its RNA 
binding cofactor trans-activation response RNA binding protein (TRBP) complex cleaves 
pre-miRs to form ~22 nt-long double-stranded miR molecules [16,17]. Next, miRs go 
through the RNA-induced silencing complex (RISC). For this purpose, mature miR 
duplexes are separated into two strands, collectively known as the guide and the 
passenger strand. The guide strand (miR), which shows the more unstable base pair at 
the 5′ end, is the one that RISC complex easily incorporates, while the passenger strand 
(miR*) undergoes degradation. The RISC complex is formed by Argonaute proteins, such 
as Ago-2, and is in charge of directing the miRs to their mRNA targets. Several other 
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enzymes take part into processes of decapping, deadenylation and subsequent 
degradation of mRNA target. 
LncRNAs, the widest subgroup of ncRNAs, exert both beneficial and detrimental 
effects by acting at transcriptional, post-transcriptional or epigenetic levels. In accordance 
with NONCODE database (http://www.noncode.org), to date there are 144,134 and 
126,415 lncRNA genes for human and mouse, respectively. Interestingly, the pool of 
annotated lncRNAs remarkably increased over the past few years (see 
http://www.lncrnadb.org/). At variance with miRs, described to have only a negative post-
transcriptional regulation on protein-coding genes [18], many of the lncRNAs functions 
remain still unknown. It has not yet been confirmed whether all of the identified lcnRNAs 
are functional, since most of them are transcribed at very low levels and can be also 
considered merely artifacts. The critical function of lncRNAs resides in their ability to 
interact with specific regulatory proteins and assembling them in complexes. In this 
sense, lncRNAs can serve as factors recruiting proteins to specific genomic loci or, once 
transcribed, they can directly open the chromatin around adjacent genes [19] acting as 
either guide, decoy or scaffold. Concerning their guidance function, lncRNAs can 
modulate gene expression by means of epigenetic regulation, acting as guides recruiting 
proteins to target genes [20]. In principle, lncRNAs can guide chromatin rearrangement in 
cis in a co-transcriptional manner via RNA polymerase II tethering, while guidance in 
trans can occur by binding to target DNA as a RNA-DNA heteroduplex, as RNA-DNA-
DNA triplex or by recognizing specific chromatin features. Conversely, by acting as 
decoys lncRNAs exploit their function of sequestering specific transcription factors, 
chromatin remodeling complexes or mainly miRs. Thus, in this review we will focus on 
the cross-talk miRNA-lncRNA and its potential role for designing future therapeutic 
strategies. 
Most lncRNA genomic loci rely on intergenic regions (long intergenic non-coding 
RNAs or lincRNAs), although they can also be found inside introns of protein-coding 
genes [21], or in genomic enhancer regions (enhancer-associated lncRNAs or 
elncRNAs). Regarding the adjacent protein-coding gene, lncRNAs can be transcribed 
from the sense or antisense strand [22]. In addition, bidirectional lncRNAs are located on 
the antisense strand of a protein-coding gene whose transcription initiates less than 1 kb 
away. In order to reach mature forms the lncRNAs, as well as other immature RNA 
transcripts, undergo several different co-transcriptional and post-transcriptional 
processes including 5ʹ-capping, splicing, polyadenylation and chemical base modification 
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[23]. In some nuclear lncRNAs, including metastasis-associated lung adenocarcinoma 
transcript 1 (MALAT1) and nuclear enriched abundant transcript 1 (NEAT1), the RNase P 
ribonucleoprotein mediates the cleavage of transport RNA (tRNA)-like structures from the 
nuclear lncRNA resulting in mature lncRNA transcripts [24,25]. Another example of 
lncRNA processing is the circular RNAs (circRNAs), a subpopulation of lncRNAs whose 
existence and function is still under debate [26]. CircRNAs are generated by means of 
special 5’- and 3’-processing such as back-splicing of introns (resulting in a circularized 
transcript with spliced 3’ sequence upstream of 5ʹ sequence) or canonical intron splicing 
(giving rise to stable by-products of splicing called circular intronic lncRNAs or ciRNAs). 
Moreover, few lncRNAs harbor miRs and, in these lncRNAs, the transcriptional 
termination as well as 3’ maturation by means of canonical polyadenylation pathway is 
not employed. Indeed, lnc-pri-miRs are produced by means of polyadenylation-
independent cleavage, and are eventually processed into both miRs and lncRNAs.  
 In contrast to miRs, which localize in the cytoplasm, most of lncRNAs seem to 
permanently reside in the nucleus. Intriguingly, a subset of lncRNAs is located in both the 
nucleus and the cytoplasm while others have been selectively localized only in the 
cytoplasm [27]. The localization of lncRNAs is critical to design an effective lncRNA-
based therapy, as the expression of nuclear lncRNAs is more effectively ablated using 
antisense oligonucleotides while the expression of cytoplasmic lncRNAs is more 
effectively knocked-out using siRNA-mediated RNA interference mechanism.  
As the ncRNAs have an intrinsic potential for clinical applications, the optimal 
delivery method needs to be exploited. To this end, several ncRNA delivery approaches 
are being investigated, including liposomes, polymers, cell penetrating peptides and 
aptamers. Liposomes for ncRNA delivery are the most promising approach due to their 
ease in preparation, their low cost and their relative non-toxicity. Moreover, lipids are very 
effective in increasing the uptake and protecting the cargo from nuclease degradation 
and renal clearance. Indeed, the use of liposomes in clinical settings has already 
undergone phase I clinical trials [28]. However, liposomes have major side effects mainly 
caused by their accumulation in liver, lungs and spleen. When the therapeutic approach 
requires lncRNA overexpression, the use of gene delivery vectors needs to be 
considered. Generally, viral-based systems exploit the use of retroviruses, lentiviruses, 
and adenoviruses or adeno-associated viruses (AAV) [29]. In addition, gene gun, 
electroporation, hydrodynamic, ultrasound, laser-based energy and inorganic carriers are 
being investigated in order to improve the efficiency of ncRNA delivery. Although these 
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innovative approaches represent promising solutions for ncRNA delivery, an effective 
gene-based therapy is still far from being obtained. 
 
2.  MiRs and cardiac development  
The heart is the first fully functioning and organized organ being developed during 
embryogenesis in humans and vertebrates. In the regulation of the complex 
developmental organization system, a crucial role is played by miRs [30]. An overview of 
miRs involved in the different stages of cardiac development is given in Figure 1. 
The miR-218 family (miR-218a-1, miR-218a-2, miR-218b) is evolutionarily 
preserved in mammals, with its host gene slit2 being essential for the proper 
development of the heart tube as seen in a zebrafish model [31]. Additionally, miR-218 
family belongs to the regulatory circuit through which tbx5 transcription factor controls 
cardiac morphogenesis. Both the overexpression of tbx5 [32] and the downregulation of 
miR-218 family caused heart-looping defects with chamber abnormalities, while the 
upregulation of miR-218-1 is able to rescue tbx5 overexpression-related cardiac defects 
[33]. Moreover, during cardiogenesis the involvement of miR-99a/let-7c in embryonic 
development has been described. While let-7c has been shown to induce cardiogenesis, 
the expression of miR-99a was shown to repress cardiogenesis by altering Nodal 
signaling and Smad2 phosphorylation levels, leading to reduced cardiac differentiation. 
Intriguingly, while these experiments were carried out in mice, the miR-99a/let-7c cluster 
was shown to be overexpressed in human Down syndrome fetal heart tissues, hinting at 
its plausible role in the congenital heart defects observed in Down syndrome patients 
[34]. 
During cardiac looping, the miR-17/92 cluster (miR-17, miR-18a, miR-19a, miR-
19b-1, miR-20a, miR-92-1) influences the differentiation of cardiac progenitors helping in 
the elongation of the heart tube, i.e. second heart field [35]. The depletion of miR-17/92 
cluster in mice has been shown to cause death after birth due to ventricular septal 
defects and lung hypoplasia, while its overexpression causes repressed fibronectin 
expression with subsequent cellular defects and overall delayed organ growth [36]. As 
the expression of the miR-17/92 cluster has been shown to increase dramatically with 
gastrulating cells differentiating into mesoderm and mesendoderm, the role of the cluster 
was investigated. Indeed it was shown that, by suppressing Bmpr2 expression at 
primitive streak, the miR-17/92 influences gastrulation and affects the regulation of actin 
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dynamics eventually leading to mesoderm invasion [37]. Similarly, the expression of miR-
143 at the onset of cardiac looping was seen to have an essential role for the formation 
and function of cardiac chambers by means of myocardial cell morphology adjustment 
[38]. 
 Muscle-specific miRs, or myomiRs (including miR-1, miR-133a, miR-208a, miR-
208b, and miR-499) have been associated with several important steps in cardiac 
commitment, and the fine regulation of myomiRs is essential for the proper embryological 
development of the heart [39]. The overexpression of miR-1 negatively regulates 
ventricular cardiomyocyte proliferation in developing mouse embryo via Hand2 mRNA 
targeting, causing thin-walled ventricles and heart failure eventually leading to embryonic 
developmental arrest [40]. Conversely, members of the miR-133a family require a stable 
level of expression as they are crucial for the growth of progenitor cells, with 
overexpression and knockdown of miR-133a reducing the proliferation of cardiomyocytes 
and hampering cardiomyogenesis respectively [41]. As the lack of miR-133a-1/miR-133a-
2 in double knockout (KO) mice resulted in growth rate increase of cardiomyocytes [41], a 
crucial role for miR-133 family in maintaining the homeostasis of cardiomyocytes has 
been suggested.  
 The two isoforms of myosin heavy chain (MyHC), i.e. α-MyHC and β-MyHC, are 
differentially regulated during embryological development of the heart, with the latter 
isoform being highly expressed in fetal life. MyomiRs-208a, -208b and -499 are encoded 
by introns of Myh6 (α-MyHC gene), Myh7 (β-MyHC gene) and Myh7b, respectively [42]. 
During embryological development Myh7 and Myh7b are highly expressed in the heart 
while Myh6 expression is detected specifically in the adult heart. Although the concurrent 
high expression of miR-208b and miR-499 during embryological development has been 
observed, it has been suggested that myosin regulatory circuitry of miRs has no role in 
fetal development [42]. By creating miR-208-KO murine models, normal expression of β-
MyHC and Myh7 was observed. Hence, myomiRs seem to primarily function in adult 
cardiac gene expression adaptation to physiological and pathological signaling [42,43].  
 MiR-15 and miR-29 families are implicated in the regulatory mechanisms 
promoting fetal to adulthood switch in cardiomyocytes, and the inhibition of miR-15 family 
(composed of miR-15a, miR-15b, miR-16-2, miR-195, and miR-497) has been associated 
with persistent cardiomyocyte mitosis [44]. Locked nucleic acid (LNA)-antagomiRs-
mediated knockdown of miR-195 in neonatal mice resulted in higher number of 
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proliferating cardiomyocytes, while the overexpression of miR-195 led to right ventricular 
hypoplasia as well as ventricular septal defects [44]. Similarly, other miRs were shown to 
have an important role in the final phases of cardiac maturation, both for cardiomyocyte 
maturation (miR-138-1 and miR-138 [45]) and ventricular wall development (miR-130a 
and miR-130b [46]).  
 Finally, miR-302-367 cluster inhibits the core components of the Hippo pathway in 
early mouse cardiac development eventually promoting cardiomyocyte proliferation. 
Conversely, the overexpression of miR-302-367 causes severe cardiomegaly and 
excessive cardiomyocyte proliferation. Intriguingly, by re-expressing miR-302-367 
postnatally the reactivation of cell cycle in cardiomyocytes was observed, resulting in 
reduced scar formation after experimental myocardial infarction [47]. It has also been 
demonstrated that miR-302-367 downregulation during the first stages of ESCs 
differentiation leads to the complete shift towards the mesendodermal lineage. This 
mechanism occurs by modulating Nodal pathway via inhibition of Lefty1 and Lefty2, i.e. 
Nodal inhibitors. Nodal signaling is crucial for the proper mesoendoderm development, 
and miR-427 controls the Nodal pathway in parallel with miR-302 [48]. Interestingly, the 
depletion of miR-427 in early stages of embryonic development of Xenopus leads to the 
reduction of brachyury levels and impairs its role in mesoderm formation and cellular 
differentiation.  
 
3.  LncRNAs and cardiac development  
The involvement of lncRNAs regulation in development has been widely 
investigated over the last years [49]. Hundreds of lncRNAs have been found to be 
cardiac-specific during development or in pathological conditions, although their 
function needs further studies [50,51]. Forty lncRNAs involved in the lateral plate 
mesoderm formation and cardiomyocyte differentiation were observed to be differentially 
expressed during embryonic carcinoma cell differentiation into cardiac myocytes [52]. 
Furthermore, during development it was found that lncRNAs function as regulators of 
key cardiac transcriptional pathways [53] with major differences in the profile expression 
of lncRNAs between embryonic and adult heart. Conversely, fewer differences were 
observed among healthy adult heart and a heart model with cardiomyopathy, suggesting 
lncRNAs primary role in cardiac development. For an overview of the most studied 
lncRNAs involved in the different stages of heart development, see Figure 1. 
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The first lncRNA identified as a key regulator in cardiac development in the 
mouse embryo was Braveheart (Bvht) [54]. Its expression has been detected in cardiac 
mesoderm and cardiomyocytes, since Bvht seems to be essential for the transition from 
nascent to cardiac mesoderm and moreover for cardiomyocyte differentiation. Indeed, 
during embryonic stem cell differentiation, the depletion of Bvht results in loss of beating 
cardiomyocytes and deactivation of genes specifying key cardiac transcription factors. 
Bvht functions upstream of the critical transcriptor factor for cardiac precursors 
mesoderm posterior basic helix-loop-helix transcription factor 1 (Mesp1) by 
sequestering suppressor of zeste 12 protein homolog (Suz12) from the promoters of 
genes that determine the cardiac lineage, including Mesp1. Suz12 is a component of the 
Polycomb Repressive Complex 2 (PRC2), which trimethylates histone H3 on lysine K27 
(H3K27me3), causing a mark that silences gene expression [55]. Therefore, Bvht 
functions as an epigenetic modulator decreasing the presence of Suz12/PRC2 in the 
promoters of cardiac-specifying genes, resulting in their expression. However, Bvht 
expression was identified in mouse ESCs and no homologs have been found in 
humans. In fact, the human orthologous genomic region is not actively transcribed. 
Nevertheless, due to the critical importance of Braveheart in cardiac lineage 
commitment, an homologous transcript could potentially be transcribed from a different 
genomic locus [49]. 
Another identified lncRNA that acts as a critical regulator in cardiac development is 
Fetal-lethal or Foxf1 adjacent non-coding developmental regulatory RNA (Fendrr) [56]. It 
is exclusively expressed in the lateral plate mesoderm and regulates its differentiation 
into the heart and ventral body wall. Disruption of the Fendrr transcript results in 
embryonic lethality, partially due to heart failure [56,57]. Similar to Bvht, Fendrr functions 
as a chromatin modulator interacting with the repressing complex PRC2, in addition to the 
activating complex trithorax-group/mixed lineage leukaemia protein (TrxG/MLL) which 
trimethylates histone H3 on lysine K4 (H3K4me3). While Bvht decreases the presence of 
PRC2 in the promoters of genes that determine cardiac lineage, Fendrr promotes 
anchorage of PRC2. Therefore, Fendrr and Bvht are likely to counteract each other in 
order to regulate the PRC2 binding on these cardiac lineage-determining gene promoters. 
Unlike Bvht, Fendrr presents the human homolog transcript FENDRR [57].  
Recently, human embryonic stem cells cardiac differentiation has provided new 
insights into the discovery and functional identification of novel human lncRNAs 
involved in cardiovascular development [49]. Kurian et al. identified two novel human 
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lncRNAs that are also necessary in cardiac development and are partially conserved 
across vertebrates [58]. TERMINATOR (expressed in pluripotent stem cells) was found 
crucial for pluripotency and early mesendodermal differentiation and survival, while 
ALIEN (expressed in cardiovascular progenitors) was found crucial for the correct 
mesodermal specification and cardiac chamber formation. 
More recently, another human lncRNA required for cardiac cell differentiation 
was identified and named cardiac mesoderm enhancer-associated non-coding RNA 
(CARMEN) [59]. In the same way as Bvht, this lncRNA functions upstream of the genes 
that specify cardiac mesoderm through epigenetic regulation. In addition, it also 
interacts with SUZ12 as well as enhancer of zeste homolog 2 (EZH2), the latter being 
another subunit of PRC2. In fact, Carmen loss-of-function experiments in mouse 
embryonic carcinoma cells revealed block of Bvht induction, suggesting that Carmen 
controls Bvht expression in mouse. Therefore, disruption of Carmen caused inhibition 
of cardiac cell fate determination and impairment of cardiomyocyte differentiation. 
Moreover, Ounzain et al. identified seven elncRNAs (mm67, -77, -85, -104, -130, 
-132 and -172) expressed during cardiomyocyte differentiation of murine embryonic 
stem cells [50]. Four of these elncRNAs (mm67, -85, -130 and -132) appear to be 
evolutionary conserved in humans. In addition, the knockdown of mm85 and SMAD7-
lncRNA specifically reduced the expression of their predicted target genes (Myocardin 
and Smad7, respectively).  
 
4.  miR-based therapy for cardiovascular diseases 
The pathological dysregulation of miRs in several cardiovascular pathologies has 
increasingly posed the question of whether miRs could be used both as diagnostic and 
therapeutic tools [60]. Table 1 summarizes a selection of therapeutic miRs in 
cardiovascular diseases, while an overview of possible therapeutic approaches by 
combining lncRNAs and miRs is depicted in Figure 2.  
In the setting of acute myocardial infarction (AMI), the use of miR-based therapies 
to prevent post-infarction cardiac remodeling, reduce the size of infarct, and stimulate 
cardiomyocyte proliferation is compelling [61]. In adult cardiomyocytes, the proliferative 
capacity aimed at heart repair following cardiomyocyte loss is restricted. In order to study 
miRs that could be potentially used to enhance adult cardiomyocyte proliferation, Eulalio 
et al. identified forty miRs that increased cardiomyocytic DNA synthesis and cytokinesis 
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[62]. In this subset of miRs, miR-590 and miR-199a were able to increase cardiac cell 
proliferation in adult animals, as well as promoting ex vivo cell cycle re-entry of adult 
cardiomyocytes. Moreover, following induction of myocardial infarction in mice, miR-590 
and miR-199a were able to reduce the infarct size by stimulating cardiomyocytes 
proliferation with recovery of cardiac functional parameters in adult mice. 
The compensatory response to several stress stimuli in the heart, including AMI, 
leads to cardiac remodeling with impaired contraction, hypertrophy of cardiomyocytes, 
and decreased ejection fraction. When untreated, chronic remodeling may eventually 
lead to heart failure (HF) and sudden death [63]. Anatomically, cardiac remodeling 
consists in a thickening of the interventricular wall and/or septum, while a reduction in 
ventricular size. This is translated into morphological changes at extracellular matrix level 
with an increased deposition of fibrotic tissue (fibrillar collagen) and infiltration, in addition 
to the cellular component. Specifically, it has been shown that both fibroblasts and 
endothelial cells re-enter the cell cycle, while cardiomyocyte pool decreases in number, 
due to the activation of their programmed death (apoptosis), necrosis or autophagy [64]. 
 As the pathological expression of several miRs has been observed in HF patients, 
it has been hypothesized that the use of miR inhibitors by blocking overexpressed miRs 
in HF may help in attenuating the pathological remodeling while improving cardiac 
function. Gupta et al. employed an aged mice model to study the effect of anti-miR22 
therapy following AMI and, compared to younger mice, old mice were shown to have 
higher expression levels of miR-22, a key regulator for cardiac autophagy [65]. 
Intriguingly, by blocking miR-22 post-AMI, the activation of cardiac autophagy led to the 
prevention of post-infarction remodeling with improved cardiac function. In a similar 
study, Montgomery et al. observed how, by inhibiting miR-208a in HF murine model, the 
cardiac remodeling was reduced together with improved cardiac function [66]. By using a 
different miR inhibitor, Bernardo et al. assessed how the administration of LNA antimiR-
652 in HF mice halted the hypertrophic remodeling associated with cardiomyopathy [67]. 
Notably, other hallmarks of heart failure including fibrosis, cardiomyocyte apoptosis and 
reduced angiogenesis, were reversed to physiological state. Similarly, Da Costa Martins 
et al. showed how the in vivo inhibition of miR-199b in mice model of HF ameliorated the 
function of the cardiac muscle, by reducing consistently fibrosis and reversing 
hypertrophy [68]. Moreover, Ucar et al. suggested that miRNA-212/132 family is pivotal 
for the cardiac hypertrophy in HF murine models [69]. Intriguingly, this study showed that, 
by inhibiting miR-132, the heart showed decreased cardiac fibrosis and preserved 
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cardiac function and dilatation, eventually preventing the development of pressure 
overload-induced HF. 
In recent years, the use of stem cell-based therapeutic strategies in cardiovascular 
diseases for the protection of endogenous cardiac progenitors and the direct use of 
differentiated cardiomyocytes has emerged. Stem cells hold the intrinsic ability of 
enhanced self-renewal, and can differentiate in several lineages and cell types. Different 
populations of stem cells have allured researchers to investigate their cardiac 
regeneration potential [70], with pluripotent stem cells (i.e. ESC and iPSC) coming under 
the spotlight as therapeutics for cardiac pathologies. ESC cells successfully differentiate 
into cardiac precursors and have been shown to contribute to the regeneration of post-
AMI heart in large animal models [71]. However, the therapeutic use of ESCs implies 
several risks, including the observed teratoma formation after transplantation of 
unpurified ESC-derived cardiomyocyte population [72]. Therefore, therapeutic strategies 
exploiting ESC regenerative capacity in the heart while avoiding the issues related with 
cell transplantation are needed. To this end, Tian et al. analyzed miRs expression during 
early embryogenesis in ESCs to identify miRs that could be used for the stimulation of 
postnatal cardiomyocyte proliferation [47]. By demonstrating the expression of miR302-
367 in early mouse cardiac development, they sought to assess whether re-expression of 
miR302-367 could increase cardiomyocyte proliferation in adult mice. Indeed, the 
increased expression of miR302-367 in cardiomyocytes increased the proliferation of 
cells, leading to eventually cardiomegaly if the miRs were expressed persistently. 
Conversely, by transiently treating mice with miR-302-367, the correct regeneration of the 
murine heart was promoted. Similarly, Khan et al. sought to explore whether exosomes 
isolated from mouse ESCs could have the same beneficial effect of ESCs in post-AMI 
[73]. Exosomes from ESCs were first analyzed, showing their enrichment of miR-291, 
miR-294, and miR-295. By administering ESCs-derived exosomes in a post-AMI murine 
model, several beneficial effects including increased vascularization, improved 
cardiomyocyte survival, as well as protection of cardiac progenitor cells survival in the 
heart were observed. Similar striking results were obtained by using a miR-294 mimic; 
hence, the authors suggested that the aforementioned effects are dependent on ESC-
exosome-mediated delivery of miR-294 [73]. 
Finally, Quattrocelli et al. reported that cardiac pericytes from dystrophic mice can 
differentiate into skeletal pericytes by means of miR-669a/q administration [74]. Notably, 
 17 
by transducing the cardiac muscle in neonatal mice with miR-669a-expressing AAV2/9 a 
partial remission from cardiomyopathies was observed. 
 
5.  lncRNA-based therapy for cardiovascular diseases 
Recently, lncRNA-based therapies have emerged for the treatment of several 
cardiac complications, such as cardiac hypertrophy, AMI and ultimately HF. In this 
context, lncRNAs are described to exert their beneficial effect by acting directly on 
specific cardiac pathways, tackling the onset of cardiovascular diseases. Cardiomyocyte 
apoptosis represents one of the most useful targets to be addressed in potential 
therapies (see section 4). One lncRNA observed in association with the apoptotic 
mechanism is cardiac apoptosis–related lncRNA (CARL), which has been described as 
an inhibitor of cardiomyocyte apoptosis targeting miR-539 [75]. An overview of possible 
therapeutic approaches by combining lncRNAs and miRs is depicted in Figure 2. In 
mouse cardiomyocytes, Carl sequesters miR-539, a microRNA binding the mRNA of the 
PHB2 subunit of prohibitin. Prohibitin is a protein present in the inner mitochondrial 
membrane [76] where it has a beneficial role in mitochondrial homeostasis acting likely 
as chaperone for respiration chain proteins. Downregulation of PHB2 during pathological 
insults, such as anoxia and ischemia/reperfusion, brings to upregulation of miR-539, 
triggering mitochondrial remodeling and subsequent cardiomyocyte apoptosis. Therefore, 
CARL functions as a miR-539 trap, regulating mitochondrial morphology and preventing 
cellular death. In conclusion, CARL has been demonstrated to reduce 
ischemia/reperfusion injury in vivo; hence, overexpression of CARL might represent a 
future strategy to counteract the cardiomyocyte loss, a common hallmark of myocardial 
infarction [75]. In contrast to the protective effect of CARL, cardiac hypertrophy related 
factor (CHRF) has been shown to trigger cardiomyocyte hypertrophy in vitro and 
apoptosis when injected in mice. Briefly, CHRF exerts its detrimental effect by targeting 
the antihypertrophic miR-489, which in turn downregulates MYD88, an important gene for 
the development of hypertrophy. Indeed, myd88-KO mice displayed resistance to 
hypertrophy caused by angiotensin II. CHRF is also well conserved in humans 
highlighting that CHRF-miR-489-MYD88 pathway might be modulated in order to define a 
tailored therapy for cardiac hypertrophy [77]. 
As described, apoptosis represents an interesting pathway to be targeted, but also 
strategies aiming to reverse cardiomyocyte autophagy might be encouraging. In this 
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regard, Viereck et al. showed that a lncRNA known as cardiac hypertrophy associated 
transcript (CHAST), acts by blocking the autophagy of cardiomyocytes while promoting 
cardiac hypertrophy [78]. Specifically, overexpression of Chast using AAV-mediated gene 
delivery induced cardiomyocyte hypertrophy in wild-type mice, whereas gapmeR-
mediated inhibition of Chast showed the opposite effect by preventing HF. Chast acts by 
modulating autophagy regulatory factor Plekhm1 levels, and the use of CHAST as a 
novel target in treating cardiac hypertrophy is promising. Moreover, a recent study 
reported that autophagy is also modulated by the lncRNA named autophagy promoting 
factor (APF), which targets miR-188-3p and ATG7 [79]. MiR-188-3p inhibits autophagy 
and myocardial infarction by targeting ATG7, while APF displays negative effects, 
triggering autophagy [79].  
Recently, the lncRNA cardiac-hypertrophy-associated epigenetic regulator 
(CHAER) has been found to be important for the development of cardiac hypertrophy. 
Chaer-KO mice show a reduced hypertrophy of the heart after transverse aortic 
constriction operation. In addition, Chaer-KO mice show an attenuated fibrosis and an 
amelioration of heart function. Mechanistically, specific region of CHAER can bind EZH2 
subunit of the repressor complex PRC2. This will bring to the inhibition of histone H3 
lysine 27 methylation in the promoter region of cardiac hypertrophy-associated genes 
[80]. Hence, the inhibition of CHAER expression could reduce cardiac hypertrophy and 
other types of heart dysfunctions. Moreover, another hypertrophic inducer is ROR 
(regulator of reprogramming) and functions as miR-133 sponge, since overexpression of 
miR-133 can reverse the pro-hypertrophic effect of ROR [81]. Conversely, a recent study 
discovered a class of anti-sense lncRNAs with cardio-protective effect, known as myosin 
heavy-chain associated RNA transcripts (MHRT or Myheart) [82]. This lncRNA is thought 
to function as a chromatin modulator, by decoying the BRG1 chromatin repressor 
complex and preventing it to recognize its targets in the genomic DNA. BRG1 is activated 
by pathological stress and results in abnormal expression of genes that ultimate cause 
cardiac myopathy and hypertrophy, as well as inhibition of MHRT expression. Therefore, 
in physiological condition, MHRT transcription can inhibit this anomalous gene 
expression and its pathological outcome [82]. Indeed, BRG1 could be used as a target to 
reduce pathological cardiac hypertrophy. Moreover, another lcnRNA has been found 
associated with cardiomyocytes in subjects affected by dilated cardiomyopathy, named 
Novlnc6. Although its role is not yet elucidated, inhibition experiments using Gapmers 
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display that down-regulation of Novlnc6, a reduction in the expression of Bmp10 and 
Nkx2.5 at mRNA level is observed [50].  
Finally, although so far there are no studies aiming to modulate the dysregulated 
immune response present in cardiac hypertrophy, emerging evidences suggest that the 
reduction of fibrotic tissue accumulated in the hypertrophic heart is also promising in 
slowing down the disease. In this regard, a novel lncRNA, known as MIAT, has been 
demonstrated to be the first pro-fibrotic lncRNA present in heart. The mechanism by 
which MIAT exerts its effects is by sequestering miR-24. Therefore, inhibition of MIAT 
paves the way for development of new anti-fibrotic strategies in the near future [83].  
 
Conclusion and remarks  
Among non-coding RNAs, miRs and lncRNAs were extensively studied in the last 
decade and some important interactions between them have been identified. 
Understanding this novel RNA crosstalk will shed light into gene regulatory networks and 
will have new implications in human development and disease. The majority of miRs are 
found during cardiac development, and their expression and distribution is reorganized 
during acute and chronic damage. LncRNAs are not only expressed during cardiac 
development, but they are also involved in adult cardiac homeostasis. In this context, 
both miRs and lncRNAs are dysregulated in pathological conditions and they were 
successfully therapeutically targeted. Recently, the academic world has established 
partnerships with biotech companies in order to develop new powerful tools, including 
nanotechnology and microvesicles as RNA delivery carriers, which are paving the way to 
establish reliable protocols for the treatment of cardiac diseases [84]. Several preclinical 
studies denoted that extracellular vesicles isolated from adult stem cells retain 
cardioprotective and proangiogenic properties when transplanted in MI animal models. 
For instance intra-cardiac injections of cardiac stem cell-derived extracellular vesicles 
reduced scar tissue and improved cardiac function in MI rat model [85]. Moreover, 
exosomes containing high amounts of microRNA-146a produced by cardiac stem cells 
were proved to ameliorate cardiac function and selective delivery of miR-146a mimics 
reproduced some of the beneficial effects of exosomes [86]. Nevertheless, exosomes 
hamper the rapid translation in clinical practice due to their complex structures and their 
potential immunogenic properties. Thus using cell factory approaches in autologous 
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setting to engineer exosome mimetics with specific miRs and lncRNAs could be an 
alternative strategy to overcome these issues. 
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Figure legends 
 
Figure 1: Overview of miRs and lncRNAs involved in cardiac development. 
Summary of current miRs and lncRNAs regulating cardiac development.  
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Figure 2: Overview of miR and lncRNA interactions. 
Summary of interactions between miRs and lncRNAs important for cardiac development 
and repair. 
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Tables 
 
Table 1: List of therapeutic miRs. 
Pathology miR 
 
Observed effect Model Reference 
AMI antimiR-22 inhibitor 
activation of cardiac autophagy, 
prevention of post-infarction 
remodeling, improved cardiac 
function 
mouse [65] 
 
  
miR-590 mimic 
Reduced infarct size, improved 
cardiac function, stimulated 
cardiomyocyte proliferation 
mouse 
[62] 
 
  
miR-199a mimic 
Reduced infarct size, improved 
cardiac function, stimulated 
cardiomyocyte proliferation 
mouse 
 
[62] 
 
 
miR302-367 mimic 
increased cardiomyocyte 
proliferation, decreased apoptosis, 
reduction in fibrotic scarring, 
increased ejection fraction, 
increased peri-infarct angiogenesis 
mouse [47] 
 
 
  
miR-294 exosome 
endogenous cardiac stem cell 
activation 
mouse [73] 
 
HF antimiR-208a inhibitor 
improved cardiac function, health 
and survival 
rat [66] 
 
antimiR-199b inhibitor 
ameliorated the function of the 
cardiac muscle, reducing 
consistently fibrosis and reversing 
hypertrophy  
mouse [68] 
 
antimiR-132 inhibitor 
suppression of pressure-overload 
and attenuated development of 
cardiac hypertrophy 
mouse 
[69] 
 
 
  
antimiR-652 inhibitor 
restored heart function, 
attenuation of adverse remodeling 
mouse [67] 
DCM  miR-669a mimic 
long term treatment showing 
reduced adverse remodeling and 
enhanced systolic fractional 
shortening of left ventricle 
mouse [74] 
AMI acute myocardial infarction, HF heart failure, DCM dilated cardiomyopathy 
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